ClinicalTrials.gg
TerminatedNCT03425435VHPE-SUpdated Feb 1, 2022

Quality of Care of Oncological Patients With HPN

An observational study in Tumors and Home Parenteral Nutrition, sponsored by Fresenius Kabi. Terminated at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-01.

Sponsored by Fresenius Kabi · Observational

Why this study was terminated
preterm stop due to low recruitment numbers during and still ongoing pandemic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
143
Ages
18 Years and older
Sex
All
01

Study summary

Medical care for patients with home parenteral nutrition (HPN) is challenging. Among other aspects, the transition from the inpatient to the outpatient setting (discharge management), the organization of HPN at home or in a care facility (care management), the expertise required to care for patients with HPN and consistent compliance with standards are key to the quality of care for patients requiring HPN.

Hospital patients on parenteral nutrition (PN) to be continued at home are often discharged at very short notice. A good interlocking of all players is required to collect and distribute the relevant information, to secure proper training for those involved and to have all utilities and equipment at hand when the patient arrives.

This study collects nutritional and clinical parameters (including patient-reported parameters) along the continuum of care of HPN patients to evaluate the impact of the quality of care of HPN patients on their quality of life.

Read the detailed description

The HPN management will be evaluated by using a self-developed patient and a standardized quality of life questionnaire.

Patients will be recruited at the participating hospital by their treating physician before discharge and will continue their study participation after discharge.

The documentation period for the individual patients will be 3 months.

The questions of the patient´s questionnaire cover areas of interest like: satisfaction with discharge management, nutrition, satisfaction with HPN.

02

Conditions studied

  • Tumors and Home Parenteral Nutrition

Browse trials for

03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's enrollment of 143 is below the median of 200 across 2,642 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Fresenius Kabi is the lead sponsor of 51 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients with solid tumors with indication for home parenteral nutrition.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women with an initial prescription for HPN during the current hospital stay
  • Planned PN must at least contain the macronutrients glucose and amino acids.
  • Solid, malignant tumor
  • Anticipated duration of the HPN is at least 28 days
  • Age ≥18 years
  • Full legal capacity or legal guardian available
  • Fluent in German language
  • Able to read and write in German language
  • Signed patient form
  • Indication for PN

Exclusion criteria

Exclusion Criteria:

  • for PN
  • performance status >3
  • Pregnant and breast-feeding women
  • Concurrent participation in another clinical study that requires deviations from the hospital's routine PN, nutrition and/or nursing procedures
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
143 participants (actual)
Patient registry
No

Interventions

  • OtherQoL and developed questionnaires for healthcare research

    Questionnaires

06

What researchers measure

Primary outcomes

  1. Patient´s questionnaire

    Mean changes in total scores of QoL-questionnaire from baseline.

    Time frame: Outcome measures obtained 1, 4 and 12 weeks after discharge from hospital

07

Study locations

1 site
  • Medizinische Hochschule Hannover
    Hannover, 30623, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Jan 2022, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2018
First posted
Feb 7, 2018
StartActual
Oct 15, 2018
Primary completionActual
Jan 14, 2022
CompletionActual
Jan 14, 2022
Last update
Feb 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03425435
Lead sponsor
Fresenius Kabi
Responsible party
Sponsor
First posted
Feb 7, 2018
Start date
Oct 15, 2018
Primary completion
Jan 14, 2022
Completion
Jan 14, 2022
Last update
Feb 1, 2022

Study contacts

Andrea Schneider, Dr. med.
principal investigator · Hannover Medical School, Germany

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion